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Abstract
Background: blood cytokines and chemokines have been proposed as biomarkers for tuberculosis (TB). Recently,
some immune mediators found in the urine of patients with renal dysfunctions have also been suggested as
potential biomarkers. Finding biomarkers for TB in urine would present several advantages over blood in terms of
collection and safety. The objective of this study was to investigate the presence of cytokines and chemokines in
the urine of patients with pulmonary TB at the time of diagnosis. In a subgroup, the evaluation was also
performed during TB treatment and at therapy completion. Patients with lung diseases other than TB, and healthy
subjects were also enrolled.
Methods: urine samples from 138 individuals, after exclusion of renal dysfunctions, were collected during an
18 month-period. Among them, 58 received a diagnosis of pulmonary TB, 28 resulted having lung diseases other
than TB, and 34 were healthy subjects. Moreover, 18 TB patients, 9 of whom were tested 2 months after AFB
smear sputum reversion and 9 of whom were cured of TB were also included. Cytokines and chemokines in urine
were evaluated using a Cytometric-Bead-Array-Flex-Set. IP-10 detection in 49 subjects was also carried out in
parallel by using an Enzyme Linked ImmunoSorbent Assay (ELISA).
Results: IFN-g, TNF-a, IL-2, IL-8, MIP-1a, MIP-1b and RANTES were poorly detected in all urine samples. Conversely,
IP-10 was consistently detected in urine and its level was significantly increased in patients with lung disease
compared to healthy subjects (p < 0.001). Increased IP-10 levels were found in both pulmonary TB and lung
diseases other than TB. Moreover lower IP-10 levels were found in cured-TB patients compared to the levels at the
time of diagnosis, and this difference was close to significance (p = 0.06). Interestingly, we demonstrated a
significant correlation between the data obtained by flow cytometry and ELISA (r
2 0.82, p < 0.0001).
Conclusions: IP-10, in contrast to IFN-g, TNF-a, IL-2, IL-8, MIP-1a, MIP-1b and RANTES, is detectable in the urine of
patients with pulmonary diseases in the absence of renal dysfunctions. Moreover, the IP-10 level in cured-TB
patients is comparable to that found in healthy subjects. More studies are needed to further investigate the clinical
utility of these findings.
Background
Tuberculosis is a leading cause of death worldwide,
especially in low-resource settings, killing 1.8 million
people each year [1]. Improved diagnostic tools that are
more sensitive and easier to perform are needed for
optimal identification and treatment of the disease [2].
Detection of the immune mediators interferon (IFN)-g,
tumor necrosis factor (TNF)-a, interleukin (IL)-2, IL-8,
macrophage inflammatory protein (MIP)-1a,M I P - 1 b,
RANTES and IFN-g inducible protein (IP)-10 in blood
have been suggested as potential biomarkers for TB
[3-9]. Specifically, serum concentrations of IL-2, IL-6
and TNF-a, shown to be increased in patients with
active TB [10-12], return to normal levels after treat-
ment [13]. Similarly, IP-10, a CXC chemokine [14,15],
has also been shown to be involved in the response to
Mycobacterium tuberculosis infection and disease.
Recent studies demonstrated that active tuberculosis
(TB) is associated with increased IP-10 plasma levels
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monitoring therapy efficacy.
Recently, several immune mediators present in the
peripheral circulation have been detected in the urine of
patients with lupus nephritis [17], acute pyelonephritis
during pregnancy [18] and in elderly subjects with urin-
ary tract infections (UTI) [19], and are proposed as bio-
markers for these kidney-related diseases.
Demonstrating that urine is a good biological sample
for TB diagnosis would represent several advantages
over blood. Collection of urine is non-invasive, does not
present biological risks for the staff involved and does
not require special equipment or highly specialized
healthcare staff. More importantly, urine can be easily
obtained in children. All these factors are highly relevant
in poor resource settings.
It has been previously shown that the neopterin, an
immune marker produced by human macrophages spe-
cifically on stimulation with IFN-g [20], is increased in
the urine of patients with several diseases as sarcoidosis
[21], celiac disease [22], multiple sclerosis [23], trans-
plants [24] and the acquired immune-deficiency syn-
drome (AIDS) [25]. In patients with active TB, urine
neopterin has been demonstrated to be a useful para-
meter for measuring the degree of disease activity and
the response to treatment [26-30].
However, to date (to our knowledge) there is no pub-
lished evidence evaluating immune mediators as cyto-
kines and chemokines, in the urine of TB patients.
Our study was designed to assess whether it is possi-
ble to detect those cytokines/chemokines known to be
associated with TB in urine in order to find potential
and useful clinical biomarkers for TB disease activity.
An evaluation of these immune mediators was per-
formed on a subgroup of patients during TB treatment
and at therapy completion. Patients with lung diseases
other than TB and healthy subjects were also enrolled.
Methods
Study participants
This study was approved by the Institutional Review
Board at INMI. All study participants gave their written
informed consent and were enrolled at the National
Institute for Infectious Diseases (INMI), Rome, Italy
from September 16
th, 2008 until February 1
st, 2010. In
Italy the incidence of TB is 7 cases per 100,000 inhabi-
tants. In Latium, the region where Rome is located,
there are approximately 10 cases per 100,000 inhabi-
tants, and about 60% of those are in immigrants [31].
Patients with suspected active pulmonary TB disease
were prospectively and consecutively enrolled before
starting therapy. Patients with past cases of TB were
excluded. After registering the eligible subjects, three
sputum samples were collected from each and all
underwent radiological examinations. The collected spu-
tum samples were processed, stained for acid fast bacilli
(AFB) microscopy by Ziehl-Neelsen method and cul-
tured in Lowenstein Jensen (BD Becton, Dickinson and
Company, Milan, Italy) and in liquid BACTEC MGIT
960 (BD Becton, Dickinson and Company, Milan, Italy).
The presence of M. tuberculosis in the positive culture
samples was further confirmed by MTD Gen-probe
based PCR (BioMérieux Inc., Marcy I’Etoile, France)
method.
TB was defined as microbiologically confirmed if
M. tuberculosis w a si s o l a t e df r o ms p u t u mc u l t u r e .C o n -
versely, patients were classified as having “clinical TB” if
the diagnosis was based on clinical and radiological cri-
teria (after excluding other diseases), including appropri-
a t er e s p o n s et oa n t i - T Bt h e r a p y( i nt e r m so fc l i n i c a l
recovery of the initial symptoms and healing of the radi-
ological lung lesions).
Patients with pulmonary diseases other than TB,
referred to as “lung diseases other than TB”,h a daf i n a l
diagnosis based on microbiology and cytological tests,
clinical signs, and successful treatment. Moreover 18 TB
patients, 9 of whom were tested 2 months after acid-fast
bacilli (ABF) smear reversion (mean time of therapy
7 1 . 2 5±1 1 . 2 5d a y s )a n d9o fw h o mw e r ec u r e do fT B
(within 12 months of completion of therapy) were also
included. As controls we included healthy laboratory
staff.
Presence of UTI in the enrolled individuals was ruled
out by evaluating bacteriuria, using an automated sys-
tem (Aution Max, Menarini, Italy & Sysmex UF100,
Dasit, Italy) and clinical criteria. Information regarding
age, sex, ethnicity, BCG status and exposure to
M. tuberculosis was collected through a structured
questionnaire. Laboratory staff evaluating the presence
of the immune factors was blinded to the status of the
patients.
Urine specimen collection and processing
Fifty ml of urine were collected from each individual in
the study. Ethylenediaminetetraacetic acid (EDTA)
[0.5 M EDTA-0.5 M Tris(hydroxymethyl)aminomethane
hydrochloride (Tris-HCl), pH 8.5], was added to a final
concentration of 40 mM within 30 min of collection,
since the content and stability of nucleic acids in these
samples was evaluated for other studies [32,33]. The
urine specimens were then stored in 4 ml aliquots and
stored at -80°C. Thawed urine samples were centrifuged
at 3,000 rpm for 10 min at 4°C before analysis.
Determination of chemokines and cytokines in urine
The quantitative determination of IFN-g,T N F - a,I L - 2 ,
IL-8, MIP-1a,M I P - 1 b, RANTES and IP-10 urine con-
centrations was carried out using a human Cytometric
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Dickinson Biosciences, San Diego, CA), analyzed by flow
cytometry (FACS Canto II, Becton Dickinson) according
to the manufacturer’s instructions. The majority of the
urine samples were tested in duplicate wells. After the
first evaluation, IP-10 (CXCL-10) was found to be the
most interesting chemokine to evaluate. We used the
same technology (according to the manufacturer’s
instructions) but only looked for IP-10. In a subgroup
of subjects, IP-10 levels were also analyzed using
Human CXCL10/IP-10 Quantikine ELISA (R&D Sys-
tems, Abingdon, UK) according to the manufacturer’s
instructions.
Statistical analysis
The main outcome of the study was the evaluation of
chemokine and cytokine production expressed as con-
tinuous (pg/ml) measures. Mean and standard deviation
(SD) were calculated: an unpaired t-test was used for
pair-wise comparisons and ANOVA was used to com-
pare means among the various groups. Differences were
considered significant at p values ≤ 0.05. SPSS v 14 for
Windows (SPSS Italia Srl, Bologna, Italy) and Prism 5
software (Graphpad Software 5.0, San Diego, CA, USA)
were used in the analysis.
Results
Characteristics of the population
Characteristics of the study participants are shown in
Table 1. Eighty-six patients hospitalized with pulmonary
symptoms suggestive of active TB were enrolled before
starting therapy. Fifty-eight of these patients were later
diagnosed with active pulmonary TB and 28 with “lung
diseases other than TB”. Forty-eight of the 58 (82.7%)
TB patients resulted microbiologically confirmed, while
10 received a final clinical diagnosis. As controls, 34
healthy subjects were included. UTI was excluded by
clinical evidence and by bacteriuria evaluation [bacter-
iuria levels of patients with pulmonary TB (mean: 1911,
SD:1988), with “lung diseases other than TB” (mean:
1944, SD:1446) and healthy subjects (mean: 1346,
SD:787). Significant differences between the groups were
found in the categories of age, origin and BCG status.
The subjects with “lung diseases other than TB” were
older than the others (p = 0.003); the origins of those
with TB were more heterogeneous compared to the
others (p < 0.0001); and those with TB were more fre-
quently BCG-vaccinated compared to the others (p <
0.0001) (Table 1)].
Cytokine and chemokine analysis
The quantitative determination of IFN-g,T N F - a,I L - 2 ,
IL-8, MIP-1a,M I P - 1 b, RANTES and IP-10 concentra-
tions in urine was performed using a human CBA Flex
Set, a flow cytometry application that allows for simulta-
neous quantification of multiple immune mediators.
All of the above -listed factors were first tested in a
subgroup of 20 individuals and the levels of the immune
mediators were almost undetectable. With the exception
of IL-8 and MIP-1b, there were no significant differ-
ences between the two groups. Note: if the concentra-
tions’ means were below 5 pg/ml, no statistical analysis
was performed (Table 2).
In contrast, urine IP-10 was detected and found to be
increased in the patients with active TB compared to
the healthy subjects. Therefore, it was analyzed in all
the enrolled individuals using the same methodology
(CBA Flex Set) but only evaluating IP-10 (see Material
and Methods). Patients with lung diseases were also
included.
A ss h o w ni nF i g u r e1 ,u r i n eI P - 1 0l e v e l si np a t i e n t s
with pulmonary TB (mean: 25.54 pg/ml, SD: 27.43)
were significantly higher than in the healthy subjects
(mean: 8.31 pg/ml, SD: 17.07) (p < 0.001). In the
patients with “lung diseases other than TB”,t h eI P - 1 0
level (mean: 23.20 pg/ml, SD: 27.26) was significantly
higher than in the healthy subjects (p = 0.011). No sig-
nificant difference between pulmonary TB patients
and patients with “lung diseases other than TB” was
observed (p = 0.71).
Measurement of IP-10 by ELISA
Technically, the CBA Flex Set method performs better
than routine ELISA because it significantly reduces the
quantity of the sample required and the time needed to
obtain the final concentration results of one or more of
the simultaneously tested immune mediators. However
it is an expensive procedure and requires the use of a
flow cytometry. Therefore, we assessed whether IP-10
detection could be performed by ELISA with similar
accuracy by evaluating the equivalent of these 2 labora-
tory procedures in 49 samples. As shown in Figure 2, a
significantly positive statistical correlation was found
between the 2 assays (r
2 0.82, p < 0.0001) indicating the
feasibility of measuring urine IP-10 levels by ELISA.
Comparison of IP-10 levels in patients on TB treatment
and after completion of therapy
To assess whether IP-10 can be used as a biomarker for
monitoring TB treatment, we evaluated the IP-10 level
in the urine of 18 patients, 9 of whom were tested 2
months after AFB smear sputum reversion and 9 of
whom were cured of TB (Figure 3, Table 1). The IP-10
level was evaluated by ELISA. Compared to patients
tested at the time of TB diagnosis (mean 32.69 pg/ml,
SD:38.82), the cured TB patients had lower IP-10 levels
(mean 11.56 pg/ml, SD:10.12) and this difference was
close to statistical significance (p = 0.06). No significant
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were compared to those tested 2 months after AFB spu-
tum reversion (mean 21.57 pg/ml, SD: 20.32) (p = 0.33).
Finally no significant difference was found between the
urine IP-10 levels evaluated in cured TB patients and
those tested 2 months after AFB sputum reversion (p =
0.20).
Discussion
In the past, urine neopterin, an immune marker pro-
duced by human macrophages [20], has been shown to
be a useful parameter for measuring the degree of dis-
ease activity and the response to treatment of patients
with active TB [26-30]. Differently, in the present proof-
of-principle study, for the first time to our knowledge,
we analyzed the urine of patients with active TB and
lung diseases other than TBf o rt h ep r e s e n c eo fo t h e r
immune mediators known to be associated with TB,
such as IFN-g,T N F - a,I L - 2 ,I L - 8 ,M I P - 1 a,M I P - 1 b,
RANTES and IP-10.
Low levels of IFN-g, TNF-a, IL-2, IL-8, MIP-1a, MIP-
1b and RANTES were found, and no differences were
observed between patients with lung diseases and
healthy subjects. In contrast, urine IP-10 levels were sig-
nificantly increased in patients with lung diseases (either
TB or non-TB related) compared to healthy subjects in
the absence of urinary infections. Moreover TB patients
tested at disease onset had higher IP-10 levels compared
to patients with cured TB, and this difference was close
to statistical significance. IP-10 results obtained by CBA
Flex Set were comparable to those obtained by ELISA,
rendering the procedure easier to perform and
Table 1 Demographic and clinical characteristics of the subjects enrolled in the study.
Total Pulmonary
TB
Lung
disease
other
than TB
Healthy
subjects
Pulmonary
TB after
2 mo AFB
smear reversion
Pulmonary
TB Cured
p value
N (%)
138 (100.0)
N (%)
58 (42.1)
N (%)
28 (20.3)
N (%)
34 (24.6)
N (%)
9 (6.5)
N (%)
9 (6.5)
Mean Age (SD) 35.87 (12.06) 32.43 (10.63) 41.89 (14.54) 38.88 (8.06) 31.60 (6.92) 32.11 (19.18) =0.003
Female gender 48 (34.8) 18 (31.0) 8 (28.6) 16 (47.1) 1 (11.1) 5 (55.6) =0.137
Origin < 0.0001
Eastern Europe 46 (33.3) 31 (53.4) 5 (17.9) - 4 (44.4) 6 (66.7)
Western Europe 49 (35.5) 10 (17.2) 4 (14.3) 32 (94.1) 1 (11.1) 2 (22.2)
Africa 14 (101) 4 (6.9) 10 (35.7) - - -
South America 7 (5.1) 2 (3.4) 1 (3.6) 2 (5.9) 1 (11.1) 1 (11.1)
Asia 22 (15.9) 11 (19.0) 8 (28.6) - 3 (33.3) -
BCG < 0.0001
BCG-positive 61 (44.2) 39 (67.2) 14 (50.0) 6 (17.6) 1 (11.1) 2 (22.2)
BCG-negative 57 (41.3) 10 (17.2) 4 (14.3) 28 (82.4) 8 (88.9) 7 (77.8)
BCG-unknown 19 (15.8) 9 (15.5) 10 (35.7) -
Pulmonary TB
microbiological diagnosis
- 48 (82.8) - - 9 (100.0) 9 (100.0)
Pulmonary TB
clinical diagnosis
- 10 (17.2) - -
Pulmonary diseases
other than TB
Pneumonia - - 16 (57.1) -
Cancer - - 2 (7.1) -
Bronchitis - - 3 (10.7) -
COPD* - - 6 (21.4) -
Pleural effusion
not TB related
- - 1 (3.6) -
Mean Bacteriuria
(SD)
1770
(1632)
1911
(1988)
1944
(1446)
1346
(787)
685
(830)
2347
(1817)
=0.352
HIV status =0.118
HIV-positive 4 (2.9) 1 (1.7) 2 (7.1) - 1 (11.1) -
HIV-negative 126 (91.3) 55 (94.8) 23 (82.1) 34 (100.0) 5 (55.6) 9 (100.0)
HIV-unknown 8 (5.8) 2 (3.4) 3 (10.7) - 3 (33.3) -
TB: tuberculosis; HIV: human immunodeficiency virus; SD: standard deviation; BCG: Bacillus Calmètte et Guerin; COPD: chronic obstructive pulmonary diseases.
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Therefore IP-10 is detectable in the urine of patients
with lung diseases and thisf i n d i n gm a yb eu s e f u lf o r
further clinical and/or research approaches.
If our results could be confirmed in additional, larger
studies this would be an important finding, especially
given the multiple advantages of collecting urine as
opposed to blood.
IP-10 is an important mediator for recruiting activated
lymphocytes into the lungs in pulmonary diseases
[15,34-36] and is involved in the response to M. tuber-
culosis [37-40] at both the site of TB disease and in
Table 2 Urinary levels of tested chemokines and
cytokines in patients with pulmonary TB and healthy
subjects.
Pulmonary TB
N. 10
Healthy subjects
N. 10
p value
pg/ml Mean ±SD
IFN-g 2.77 (0.44) 2.78 (0.13) NA
TNF-a 1.10 (0.69) 0.91 (0.51) NA
IL-2 0.45 (1.02) 0 (0) NA
IL-8 54.84 (128.40) 53.66 (110.00) 0.98
MIP-1 a 2.47 (0.93) 0.60 (1.01) NA
MIP-1 b 11.77 (9.92) 14.31 (22.29) 0.67
RANTES 2.87 (1.82) 4.82 (3.79) NA
N: number; SD: standard deviation, IFN: interferon, TNF: tumor necrosis factor,
IL: interleukin, MIP: macrophage inflammatory protein, RANTES: regulated on
activation normal T cell expressed and secreted; NA: not available if the
means are below 5 pg/ml.
Figure 1 Urine IP-10 is associated with pulmonary lung
diseases. Urine IP-10 concentrations from healthy subjects, patients
with pulmonary TB and “lung diseases other than TB” are reported.
Horizontal bars indicate the means. IP-10 was measured by the CBA
Flex Set and the data were analyzed by flow cytometry. The
statistical significance of the results was evaluated by using the
t-test, and differences were considered to be significant when the
p-values (indicated by the numbers) were ≤ 0.05.
Figure 2 Positive correlation between the Urine IP-10 levels
detected by ELISA and by CBA Flex Set analyzed by flow
cytometry. Urine IP-10 concentrations were evaluated in parallel by
ELISA and by CBA Flex set analyzed by flow cytometry. A
significantly positive statistical correlation was found between the 2
assays (r
2 0.82, p < 0.0001).
Figure 3 Overtime evaluation of IP-10 level in patients
undergoing TB treatment and after therapy completion. Urine
IP-10 concentration was evaluated by ELISA in patients at the time
of TB diagnosis, 2 months after AFB sputum reversion and after
therapy completion. Horizontal bars indicate the means. The
statistical significance of the results was evaluated by using the
t-test. A statistical difference close to significance was found
between the IP-10 levels at the time of TB diagnosis and after
therapy completion (p = 0.06).
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10 in the pleural effusions of TB patients [41], whereas
Azzurri described high levels of IP-10 in the plasma of
patients with active pulmonary TB, which subsequently
decreased after successful anti-TB treatment. These data
from the literature may imply that IP-10 is a potential
marker for lung diseases and therapy monitoring.
Our results suggest that urine concentrations of IP-10
may have the same course during TB treatment as that
recorded in plasma, and thus propose that urine levels
of this chemokine should be evaluated as a potential
biomarker for monitoring TB treatment.
Regarding the presence of IP-10 in urine, previous stu-
dies have shown its detection only in kidney-related dis-
eases. In particular, higher urine IP-10 concentrations
were found during urosepsis and in those with febrile
urinary tract infections compared to healthy subjects,
accompanied by a significant decrease following success-
ful therapy [42,43]. Interestingly, IP-10 concentrations
were also increased in human urine upon experimentally
induced endotoxemia [43]. Furthermore, reports have
shown an increase of mRNA IP-10 levels in the urine of
patients with autoimmune diseases, such as class IV
of lupus nephritis, when compared to other classes of
lupus nephritis [44].
We also adjusted the IP-10 concentrations in urine
with creatinuria and with the urine specific gravity in
order to exclude any dilution factor as responsible for
the results obtained, as previously shown [30]. However,
significant differences were still found between the
ratios of the healthy subjects compared to both groups
of patients, with pulmonary TB or with lung diseases
other than TB, even after these adjustments.
T h ep r e s e n ts t u d yh a san u m b e ro fl i m i t a t i o n s .T h e
evaluation of IP-10 as a marker for therapy efficacy was
performed only in patients with TB, excluding those
with lung diseases other than TB. The comparison
between patients with active TB, on treatment and after
completion of therapy was performed by cross-sectional
evaluation, not using a formal longitudinal study. How-
ever, despite these limitations, the study shows a certain
consistency of the data obtained among all the patients
with lung disease in terms of higher detection of IP-10
compared to the healthy subjects. Moreover, although of
a cross-sectional design, the study shows a strong trend
for lower concentrations of IP-10 in urine following
successful TB treatment. Although a moderate number
of patients were enrolled (138), certainly larger studies
are needed to evaluate the robustness of these results.
Conclusions
For the first time, IP-10 (in contrast to IFN-g,T N F - a,
IL-2, IL-8, MIP-1a,M I P - 1 b and RANTES) has been
detected in the urine of patients with lung disease in
the absence of renal illnesses. In those with active TB,
its level may decrease after completion of TB therapy.
Further studies are needed to substantiate our
findings.
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